Friday’s BioPlay is Xoma Ltd. (Nasdaq:XOMA)

LOS ANGELES, CA- 05/05/09- BioMedReports.Com, the news portal covering the biomedical sector that delivers financial and investment intelligence to a community of highly informed investors has issued a report on Xoma Ltd. (XOMA). On Thursday (06/04/09) shares closed up 38%, a gain analysts pinned on anticipation that the drug company will release positive data on its Type II diabetes treatment during a presentation this weekend.

In research notes Thursday, analysts said the new Phase I data on the drug, XOMA 052, should be strong since Xoma released positive initial Phase I results for the treatment in September. The presentation will be made at the American Diabetes Association conference in New Orleans on Saturday.

An audiocast of the presentation will be available live via the Investors tab at the XOMA website, www.xoma.com. An archived version of the webcast will be available for 90 days following the presentation.

“The data at ADA will likely add further support to the potential efficacy of XOMA 052,” RBC Capital Markets analyst Jason Kantor wrote.

The complete Phase I results on the drug are expected to be released this summer.

Shares closed at $1.18, after earlier climbing as high as $1.21. The stock has gained 90% year to date, but is still 38% below its year-ago level.

The full article appears today at BiomedReports.com:

http://biomedreports.com/articles/most-popular/1160-fridays-bioplay-xoma-ltd-nasdaqxoma.html

Biotech investors interested in seeing the complete database of clinical trials and upcoming FDA decisions can access that information here:

http://biomedreports.com/component/content/article/548.html


Please remember to subscribe or sign up for our free newsletter to get news like this from BioMedReports delivered to your mailbox before the markets open.


####

About BioMedReports.Com

BioMedReports.com is a news portal covering the biomedical news and financial sector. It features its own blog, discussion forum, stock research reports, news feeds, videos, press release capability, stock commentaries, and other unique content - including FDA and Clinical Trial Calendars.

For more biomedical sector and investment news, go to BioMedReports.com

Disclosure: No positions.

Certain sections of this report contain forward-looking statements that are based on our reporters’ expectations, estimates, projections and assumptions. Words such as “expects,” “anticipates,” “plans,” “believes,” “scheduled,” “estimates” and variations of these words and similar expressions are intended to identify forward-looking statements, which include but are not limited to projections of revenues, earnings, segment performance, cash flows, contract awards, FDA announcements, trial and drug approvals, and company stability. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors including but not limited to the status or outcome of legal and/or regulatory proceedings.

All forward-looking statements speak only as of the date of this report or, in the case of any document incorporated by reference, the date of that document. All subsequent written and oral forward-looking statements attributable to the company or any person acting on the company’s behalf are qualified by the cautionary statements in this section. BiomedReports.Com does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this report.

Contact Information

M.E. Garza

Editor

BioMedReports.Com

Contact via E-mail